STAT

Opinion: 3 tips for successful global pharma collaboration and licensing agreements

Global partnerships are becoming the lifeblood of large #pharma companies and small #biotech startups. Here's how to make them a success.

Partnerships have long been the lifeblood of both large pharmaceutical companies and small biotech startups. Today, small biotech companies increasingly have the upper hand, as innovative technologies disrupt the competitor landscape and rich capital markets have lessened the necessity for deal-making.

These factors give biotech companies more choices in how to fund their research and development as well as how they commercialize new products. They also provide enhanced leverage in selecting partners and negotiating contract details. As a result, transformational global collaborations across the industry

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks